Company repurchased 5,000,000 shares of common stock from Oaktree-affiliated funds at $12.42 per share on August 20, 2025.
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Olivier Rabiller
Also a director
President & Chief Executive Officer
|
55 | Not stated | $9,438,607 | |
|
Sean Deason
Senior Vice President & Chief Financial Officer
|
54 |
Since 2020
6 years
|
$3,185,537 | |
|
Craig Balis
Senior Vice President & Chief Technology Officer
|
61 |
Since 2018
8 years
|
$2,316,028 | |
|
Joanne Lau
Vice President, Chief Accounting Officer and Corporate Controller
|
49 |
Since 2021
5 years
|
Not reported | |
|
Mark Rollinger
Senior Vice President, General Counsel & Corporate Secretary
|
56 | Not stated | Not reported | |
|
Daniel Deiro
SVP, GCM & GM Japan/Korea
Title from the Form 4 dated Sep 1, 2026
|
53 | Not stated | Not reported | |
|
Thierry Mabru
Senior Vice President, Integrated Supply Chain
|
58 | Not stated | $2,292,141 | |
|
Nils Martens
Senior Vice President, Strategy, Business Development & Advanced Technologies
|
41 | Not stated | Not reported | |
|
Mark Rodrigues
SVP, GM GBEs Turbo Tech
Title from the Form 4 dated Jun 24, 2026
|
54 | Not stated | Not reported | |
|
Fabrice Spenninck
SVP & Chief Human Res. Officer
Title from the Form 4 dated Apr 30, 2026
|
57 | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 10, 2026 · updated by the 8-Ks of Jul 27, 2026 and Oct 28, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Daniel Ninivaggi
Board chair
|
61 |
2021
5 years
|
Independent |
Technology & Innovation Committee
|
Indivior Pharmaceuticals Inc., a specialty pharmaceuticals company, since January 2025 | $404,459 | |
|
Olivier Rabiller
CEO
|
55 |
2018
8 years
|
Not stated |
Technology & Innovation Committee
|
None stated | Paid as CEO | |
|
Paul Camuti
|
64 |
2024
2 years
|
Independent |
Nominating & Governance Committee · Chair
|
None stated | $269,570 | |
|
Joachim Drees
|
61 |
2024
2 years
|
Independent |
Audit Committee
|
None stated | $275,123 | |
|
D’Aun Norman
|
59 |
2021
5 years
|
Independent |
Audit Committee · Chair
|
PHINIA Inc. (NYSE: PHIN) | $276,650 | |
|
Julia Steyn
|
50 |
2021
5 years
|
Independent |
Technology & Innovation Committee
|
None stated | $275,428 | |
|
David J. Crompton
Joined Jul 21, 2026
|
- | - | Independent |
Technology & Innovation Committee
|
- | - | |
|
Robert Shanks
Leaving at the meeting
|
Not stated | Not stated | Not stated | None stated | None stated | $273,354 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Company repurchased 5,000,000 shares of common stock from Oaktree-affiliated funds at $12.42 per share on August 20, 2025.
Company repurchased 2,500,000 shares of common stock from Oaktree-affiliated funds at $16.26 per share on November 3, 2025.
Loading...